International journal of clinical practice
-
Int. J. Clin. Pract. · Aug 2021
Evaluating the Likelihood to be Helped or Harmed after Treatment with Viloxazine Extended-Release in Children and Adolescents with Attention Deficit/Hyperactivity Disorder.
When clinicians evaluate potential medications for their patients, they must weigh the probability of a treatment's benefits against the possible risks. To this end, the present analyses evaluate the novel nonstimulant viloxazine extended-release (viloxazine ER) using measures of effect size to describe the potential benefits of its treatment in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) as well as the risk of discontinuation because of intolerable adverse events. ⋯ These results indicate that patients with ADHD are likely to benefit from treatment with viloxazine ER, and are unlikely to discontinue, as viloxazine ER treatment was associated with favourable LHH, NNT, and NNH values. Clinicaltrials.gov: NCT03247530, NCT03247543, NCT03247517, NCT03247556.
-
Int. J. Clin. Pract. · Aug 2021
Relationship between door-to-balloon time and clinical experience level of emergency department physicians.
This study aimed to investigate the relationship between the experience level of physicians initially making the clinical diagnosis of ST-segment elevation myocardial infarction in the emergency department and door-to-balloon time (DBT). ⋯ DBT decreased as the experience level of the emergency physician increased, but randomisation is required to determine the clinical benefit of this effect.
-
Int. J. Clin. Pract. · Aug 2021
The incidence and risk factors for early death among patients with oral tongue squamous cell carcinomas.
The objective of this study is to evaluate the early mortality rate and associated factors for early death in oral tongue squamous cell carcinomas (OTSCC) patients. ⋯ Our results showed that a total of 3.6% patients with OTSCC suffered early death. Predictors of early death are primarily related to age older than 60 years, advanced T stage, advanced N stage, distant metastasis and no surgery but also include unmarried status, but better prognostic and predictive tools in larger sample to select early death patients are needed.
-
Int. J. Clin. Pract. · Aug 2021
Circulating CD15+ LOX-1+ PMN-MDSCs are a potential biomarker for the early diagnosis of non-small cell lung cancer.
Non-small-cell lung cancer (NSCLC) is the most common clinical lung cancer. Polymorphonuclear-myeloid derived suppressor cells (PMN-MDSCs), which are the major population of MDSCs, are involved in NSCLC progression. Recently, it was found that lectin-type oxidized LDL receptor 1 (LOX-1) could identify human PMN-MDSCs. However, the role of CD15+ LOX-1+ PMN-MDSCs in NSCLC early diagnosis has not been revealed. Here, we tried to confirm the application of the newly identified CD15+ LOX-1+ PMN-MDSCs in the early diagnosis of NSCLC. ⋯ Circulating CD15+ LOX-1+ PMN-MDSCs are a potential diagnostic marker for NSCLC, and are associated with NSCLC prognosis and recurrence after surgery.
-
Int. J. Clin. Pract. · Aug 2021
The Effect of Pulmonary Rehabilitation Program on Work Productivity and Clinical Parameters in Patients with Ankylosing Spondylitis.
The objective of the present study was to investigate the effect of the Pulmonary Rehabilitation Programme on work productivity, disease activity, functional status, quality of life, respiratory function tests (RFTs), physical capacity and depression in ankylosing spondylitis (AS) patients. ⋯ Pulmonary Rehabilitation Programme was found to be an effective method of improving work productivity in AS patients. Also, the Pulmonary Rehabilitation Programme has positive effects on disease activity, functional status, physical capacity, depression level, and quality of life.